AbbVie Inc sues Dr Reddys for infringement of thyroid injection patent

19 Jun 2013 Evaluate

US-based drug maker AbbVie Inc, the spun-off entity of Abbott, has sued Dr Reddys Laboratories for purportedly infringing the former’s patented drug Zemplar on six counts, concerning three patents. AbbVie has demanded the court to pass an order to hold back Dr Reddys from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing Dr Reddys' generic paricalcitol injectable products prior to the expiration of said patents.

Earlier, Dr Reddys filed an ANDA (Abbreviated New Drug Application) with the US Food and Drug Administration (US FDA), seeking approval to sell a generic copy of US drug maker’s Zemplar injectable products in 2 microgram/ml and 5 microgram/ml formulations, prior to the expiration of the patents owned by and exclusively licensed to the complainants.

Dr. Reddys Lab Share Price

1294.50 20.45 (1.61%)
20-Mar-2026 13:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1773.40
Dr. Reddys Lab 1294.50
Cipla 1256.00
Zydus Lifesciences 889.70
Lupin 2318.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×